Advanced Gastric Cancer with Liver and Lymph Node Metastases Successfully Resected after Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil

Abstract

Background: At diagnosis, about 35% of patients with gastric cancer present with distant metastases, and most patients with gastric cancer and liver metastases are excluded from curative surgery. Case: We report a case of human epidermal growth factor receptor-2 (HER2)-negative gastric cancer with metastases to the liver and perigastric lymph nodes. The patient (a 60-year-old man) was considered unresectable at diagnosis and was treated with palliative chemotherapy (docetaxel plus cisplatin and 5-fluorouracil by continuous intravenous infusion over 5 days every 3 weeks). However, after 6 courses of chemotherapy, a computed tomography scan showed a reduction of the liver metastasis and the disappearance of the enlarged perigastric lymph nodes. The patient then underwent a curative gastrectomy, lymphadenectomy and liver resection. After surgery, the patient was treated with 6 courses of FOLFOX-4 regimen as adjuvant chemotherapy. With a follow-up of 26 months after surgery, the patient is alive and disease free. Conclusion: In patients with metastatic gastric cancer, the prognosis is poor with a median overall survival of 11 months since curative treatments are excluded; however, this case illustrated that a personalized treatment with chemotherapy and surgery can allow a curative strategy in selected patients with HER2-negative advanced gastric cancer.

RNF43 and PWWP2B inhibit cancer cell proliferation and are a treatment biomarker of gastric cancer patients and their response to FDA-approved drugs

“…The downstream protein GSK3ß is major AKT substrate. Docetaxel trihydrate is used widely to treat recurrent or gastric cancer [31,32]. Docetaxel treatment inhibit phosphorylation state of GSK3ß [33].…”

RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer

“…The downstream protein GSK3ß is major AKT substrate. Docetaxel trihydrate is used widely to treat recurrent or gastric cancer [30,31]. Docetaxel treatment inhibit phosphorylation state of GSK3ß [32].…”

Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis

“…Although new compounds have been developed to be active against transitional cell carcinoma, Cisplatin remains one of the most active ‘standard’ single-agents and the mainstay of typical combination regimens against gastric cancer [22–26]. However, Cisplatin is highly toxic, and its efficacy is limited owing to its adverse events.…”